title: Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
abstract: The current live-orthopoxvirus vaccine is associated with minor to serious adverse affects, and is contraindicated for use in a significant portion of the population. As an alternative vaccine, we have previously shown that a DNA subunit vaccine (4pox) based on four orthopoxvirus immunogens (L1R, B5R, A27L and A33R) can produce protective immunity against lethal orthopoxvirus challenges in mice and nonhuman primates. Because antibodies are critical for protection against secondary orthopoxvirus infections, we are now interested in strategies that will enhance the humoral immune response against vaccine targets. Here, we tested the immunogenicity of an L1R construct to which a tissue plasminogen activator signal sequence was placed in frame with the full-length L1R gene. The tPA-L1R construct produced a more robust neutralizing antibody response in vaccinated mice when the DNA vaccine was administered by gene-gun as a prime/single boost. When the tPA-L1R construct was substituted for the unmodified L1R gene in the 4pox vaccine, given as a prime and single boost, animals were better protected from lethal challenge with vaccinia virus (VACV). These findings indicate that adding a tPA-leader sequence can enhance the immunogenicity of the L1R gene when given as a DNA vaccine. Furthermore, our results demonstrate that a DNA-based vaccine is capable of establishing protection from lethal orthopoxvirus challenges when administered as a prime and single boost without requiring adjuvant.
authors.affiliation: Department of Molecular Virology, Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, United States.
authors.forename: Joseph W
authors.initials: JW
authors.lastname: Golden
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Josleyn
authors.forename: Jay W
authors.initials: JW
authors.lastname: Hooper
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D019470:Biolistics; D001835:Body Weight; D007117:Immunization, Secondary; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D010960:Plasminogen Activators / Q000235:genetics; D021382:Protein Sorting Signals; D021381:Protein Transport / Q000276:immunology; D012900:Smallpox Vaccine / Q000235:genetics / Q000276:immunology*; D016019:Survival Analysis; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology; D022223:Vaccines, Subunit / Q000235:genetics / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*
chemical_list: D000914:Antibodies, Viral; C087715:L1R protein, Vaccinia virus; D021382:Protein Sorting Signals; D012900:Smallpox Vaccine; D019444:Vaccines, DNA; D022223:Vaccines, Subunit; D014759:Viral Envelope Proteins; D010960:Plasminogen Activators